drugset / Trial / NCT07596199

A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women

NCT07596199

Phase 3 Recruiting 95 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this Phase 3, non-randomized, single-arm, open-label study is to evaluate the immune response, reactogenicity and safety of GSKs dTpa vaccine in Japanese pregnant women between 27 weeks and less than 37 weeks of pregnancy. Both the pregnant women and their neonates born during the study will be evaluated for specific analyses.

Timeline

Start
2026-06-29
Primary completion
2026-12-11
Completion
2027-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject DTPa Vaccine Intramuscular

Indications

No indication recorded.